CD40LG and systemic lupus erythematosus: Several molecules for SLE treatment are currently at advanced stages of research trial (Phase III and IV studies) and may provide novel therapeutic strategies for SLE: Tabalumab and Blisibimod that are binding B-cell activating factor (BAFF), Dapirolizumab pegol, an anti-CD40L Fab’ fragment, Anifrolumab, a human monoclonal antibody to type I interferon receptor subunit [45], and the dual-target biological agents telitacicept, which is a novel recombinant TACI-Fc fusion protein able to inhibit BAFF and A proliferation inducing ligand (APRIL) cytokines at the same time [43,44].